Executive Summary

JN.1 is currently the most prevalent SARS-CoV-2 variant globally. Considering the available evidence, the additional public health risk posed by JN.1 is still evaluated as low at the global level. Current population immunity globally as well as immunity generated by the XBB.1.5 booster vaccination is expected to remain cross-reactive to this variant against symptomatic and severe disease. Therefore, the continued spread of this variant alone is unlikely to increase the burden on national public health systems compared to other Omicron sub-lineages.

Updated Risk Evaluation of JN.1, 15 April 2024

JN.1 is a descendent lineage of BA.2.86, with the earliest sample collected on 25 August 2023 (1).

As of 6 April 2024, there were 162,773 JN.1 sequences submitted to GISAID (1) from 121 countries, representing 93.7% of the globally available sequences in epidemiological week 12 (18 to 24 March 2024). This is a rise in prevalence from 91.8% four weeks prior in epidemiological week 8 (19 to 25 February 2024, Table 1). The JN.1 variant is also the most prevalent SARS-CoV-2 variant in all four WHO regions with consistent sharing of SARS-CoV-2 sequences at epidemiological week 12 (93.9% for the Western Pacific region (WPR), 85.7% for the South East Asia region (SEAR), 94.7% for the European region (EUR), and 93.2% for the region of the Americas (AMR)).

Table 1: Global proportions of SARS-CoV-2 Variants, weeks 8 to 12 of 2024

<table>
<thead>
<tr>
<th>Lineage</th>
<th>Countries§</th>
<th>Sequences§</th>
<th>2024-08</th>
<th>2024-09</th>
<th>2024-10</th>
<th>2024-11</th>
<th>2024-12</th>
</tr>
</thead>
<tbody>
<tr>
<td>VOIs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>XBB.1.5</td>
<td>143</td>
<td>377,836</td>
<td>0.2</td>
<td>0.3</td>
<td>0.3</td>
<td>0.0</td>
<td>0.1</td>
</tr>
<tr>
<td>XBB.1.16</td>
<td>131</td>
<td>126,607</td>
<td>0.2</td>
<td>0.1</td>
<td>0.2</td>
<td>0.2</td>
<td>1.1</td>
</tr>
<tr>
<td>EG.5</td>
<td>112</td>
<td>213,938</td>
<td>1.9</td>
<td>1.8</td>
<td>1.2</td>
<td>1.1</td>
<td>1.1</td>
</tr>
<tr>
<td>BA.2.86</td>
<td>88</td>
<td>212,212</td>
<td>2.3</td>
<td>1.9</td>
<td>1.6</td>
<td>1.3</td>
<td>1.4</td>
</tr>
<tr>
<td>JN.1</td>
<td>119</td>
<td>157,686</td>
<td>91.8</td>
<td>92.1</td>
<td>93.0</td>
<td>93.2</td>
<td>93.7</td>
</tr>
<tr>
<td>VUMs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>XBB</td>
<td>147</td>
<td>108,373</td>
<td>0.1</td>
<td>0.1</td>
<td>0.0</td>
<td>0.1</td>
<td>0.1</td>
</tr>
<tr>
<td>XBB.1.9.1</td>
<td>128</td>
<td>99,354</td>
<td>0.1</td>
<td>0.1</td>
<td>0.1</td>
<td>0.1</td>
<td>0.1</td>
</tr>
<tr>
<td>XBB.2.3</td>
<td>121</td>
<td>52,137</td>
<td>0.2</td>
<td>0.2</td>
<td>0.3</td>
<td>0.3</td>
<td>0.2</td>
</tr>
<tr>
<td>Unassigned</td>
<td>75</td>
<td>30,446</td>
<td>0.1</td>
<td>0.1</td>
<td>0.1</td>
<td>0.1</td>
<td>0.2</td>
</tr>
</tbody>
</table>

Figures by WHO, data from GISAID.org, extracted on 06 March 2024.
Number of countries and sequences are since the emergence of the variants.
The variants listed include descendant lineages, except those individually specified elsewhere in the table.
The VOI and the VUMs that have shown increasing trends are highlighted in orange, those that have remained stable are highlighted in blue, while those with decreasing trends are highlighted in green.

WHO and its Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC) continue to regularly assess the impact of variants on the performance of COVID-19 vaccines to inform decisions on updates to vaccine composition (2).

The risk evaluation below follows the WHO framework (3) and is based on currently available evidence.
Overall risk evaluation:

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Evidence</th>
<th>Level of risk</th>
<th>Level of confidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Growth advantage</td>
<td>Based on its genetic features, JN.1 possesses some antigenic advantage evading previous immunity. The available evidence on JN.1 does not suggest additional public health risks relative to the other currently circulating Omicron descendent lineages. Available limited evidence does not suggest that the associated disease severity is higher as compared to other circulating variants.</td>
<td>High</td>
<td>High</td>
</tr>
<tr>
<td>Immune escape</td>
<td>Multiple studies using live viruses (5-10) and pseudo-viruses (11-25) have found reduced neutralization of JN.1 by human sera. The majority of these studies have found JN.1 to be more evasive than other recently circulating Omicron sublineages, such as EG.5 or XBB.1.5. However, several studies have found similar neutralization of JN.1 and one or several recent Omicron sublineages. Where JN.1</td>
<td>Moderate</td>
<td>High</td>
</tr>
</tbody>
</table>

* see footnote for more explanations
has been found to be more immune evasive, the drop in neutralization titer is typically modest and many individuals retain some neutralization.

Vaccination with an XBB.1.5 monovalent booster has been shown by multiple studies to increase neutralization titers against JN.1 (5-6, 11-17). Effectiveness of the XBB.1.5 monovalent booster at protecting from symptomatic JN.1 infection has been estimated at between 19% to 49% in different studies from the US (26-27).

Pre-existing SARS-CoV-2-specific T cells are predicted to cross-recognize BA.2.86, whereby 72% and 89% of CD4 and CD8 SARS-CoV-2 responses are still conserved in BA.2.86 (28).

** see footnote for more explanations

| Severity and clinical/diagnostic considerations | There have been no reports of changes in disease severity in studied patients. The infectivity of JN.1 pseudo-virus in CaLu-3 cells has been shown to be similar to XBB.1.5 and lower than BA.2.86 (20). Further, a study examining ICU patients in France found no difference in severity of illness, requirement for mechanical ventilation or mortality at 28 days between JN.1 and XBB (29).

One study showed no activity of the monoclonal antibody Sotrovimab against JN.1 (30). The same study found similar in vitro activity of Nirmatrelvir, Remdesivir and Molnupiravir against BA.2.86.1 as against XBB.1.16.1 and EG.5.1.3 (30).

*** see footnote for more explanations | Low | Moderate |
Annex:

* Growth advantage

*Level of risk*: High, as the variant is dominant across all WHO regions with consistent SARS-CoV-2 sequence data sharing and contains sub-variants that are the fastest growing among the currently circulating SARS-CoV-2 variants.

*Confidence*: High, as the variant is dominant across all WHO regions and its expansion is reflected in wastewater surveillance.

** Antibody escape**

*Level of risk*: Moderate, as it is estimated that JN.1 has increased immune evasion relative to co-circulating variants.

*Confidence*: High, as there are increasing data on cross neutralization of JN.1 from varied population immunity backgrounds.

*** Severity and clinical considerations***

*Level of risk*: Low, as currently there are no reports of elevated disease severity associated with this variant.

*Confidence*: Moderate. There have been several studies looking at disease severity in SARS-CoV-2 infected patients, and JN.1 has been the dominant variant for several months with no reports of elevated disease severity. However, additional studies would be needed to further assess the impact of this variant on clinical outcomes. Although, there is regular co-ordination and data sharing between all WHO Regional colleagues, countries, and partners, reporting of new hospitalizations and ICU data with the WHO has decreased substantially, therefore caution should be taken when interpreting severe cases due to this decrease in reporting.
References

1. GISAID. Available from: https://gisaid.org/hcov19-variants/
6. Jain, S. et al. XBB.1.5 monovalent booster improves antibody binding and neutralization against emerging SARS-CoV-2 Omicron variants. 2024.02.03.578771 Preprint at https://doi.org/10.1101/2024.02.03.578771 (2024).
7. Peled, Y. et al. Sixth monovalent XBB.1.5 vaccine elicits robust immune response against emerging SARS-CoV-2 variants in heart transplant recipients. The Journal of Heart and Lung Transplantation (2024) doi:10.1016/j.healun.2024.03.014.
11. Roederer, A. L. et al. Ongoing evolution of SARS-CoV-2 drives escape from mRNA vaccine-induced humoral immunity. 2024.03.05.24303815 Preprint at https://doi.org/10.1101/2024.03.05.24303815 (2024).
16. Wang, Q. et al. SARS-CoV-2 Omicron BA.2.87.1 Exhibits Higher Susceptibility to Serum Neutralization Than EG.5.1 and JN.1. 2024.03.10.584306 Preprint at https://doi.org/10.1101/2024.03.10.584306 (2024).
17. Abul, Y. et al. Broad immunogenicity to prior SARS-CoV-2 strains and JN.1 variant elicited by XBB.1.5 vaccination in nursing home residents. 2024.03.21.24303684 Preprint at https://doi.org/10.1101/2024.03.21.24303684 (2024).

20. Li, P. et al. Distinct Patterns of SARS-CoV-2 BA.2.87.1 and JN.1 Variants in Immune Evasion, Antigenicity and Cell-Cell Fusion. 2024.03.11.583978 Preprint at https://doi.org/10.1101/2024.03.11.583978 (2024).


25. He, X. et al. Heterogeneous hybrid immunity against Omicron variant JN.1 at 11 months following breakthrough infection. 2024.03.02.583082 Preprint at https://doi.org/10.1101/2024.03.02.583082 (2024).


